- Title
- Targeting apoptotic pathways in acute myeloid leukaemia
- Creator
- Sillar, Jonathan R.; Enjeti, Anoop K.
- Relation
- Cancers Vol. 11, Issue 11, no. 1660
- Publisher Link
- http://dx.doi.org/10.3390/cancers11111660
- Publisher
- MD PIAG
- Resource Type
- journal article
- Date
- 2019
- Description
- Acute Myeloid Leukaemia is a devastating disease that continues to have a poor outcome for the majority of patients. In recent years, however, a number of drugs have received FDA approval, following on from successful clinical trial results. This parallels the characterization of the molecular landscape of Acute Myeloid Leukaemia (AML) over the last decade, which has led to the development of drugs targeting newly identified recurring mutations. In addition, basic biological research into the pathobiology of AML has identified aberrant programmed cell death pathways in AML. Following on from successful outcomes in lymphoid malignancies, drugs targeting the B Cell Lymphoma 2 (BCL-2) family of anti-apoptotic proteins have been explored in AML. In this review, we will outline the preclinical and clinical work to date supporting the role of drugs targeting BCL-2, with Venetoclax being the most advanced to date. We will also highlight rationale combinations using Venetoclax, ongoing clinical trials and biomarkers of response identified from the early phase clinical trials performed.
- Subject
- acute myeliod leukaemia; programmed cell death; BCL-2; MCL-1; BH3 mimetic; apoptosis
- Identifier
- http://hdl.handle.net/1959.13/1451054
- Identifier
- uon:44081
- Identifier
- ISSN:2072-6694
- Rights
- © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- Language
- eng
- Full Text
- Reviewed
- Hits: 624
- Visitors: 690
- Downloads: 68
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 265 KB | Adobe Acrobat PDF | View Details Download |